psoriasis

Merola JF, Ferris LK, Sobell JM, Sofen H, Osborne J, Vaile J, Jou YM, Daamen C, Scotto J, Scharnitz T, Lebwohl M. Deucravacitinib: Adverse Events[...]

By sjmartinez • February 8, 2025

Perez-Chada LM, Gondo G, Grant C, Woodbury M, Kucharik AH, Armstrong AW, Eder L, Mease P, Ogdie A, Strand V, Gottlieb AB, Merola JF. Construct[...]

By sjmartinez • January 27, 2025

Gooderham MJ, Mrowietz U, Kadus W, Drda K, Gu H, Vangerow H, Flack M, Korell J, Sofen H, Papp KA. Phase II Randomized Trial of[...]

By sjmartinez • January 24, 2025

Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and Safety[...]

By sjmartinez • December 26, 2024

Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb AB, Gold LS, Korman NJ, Lio P, Merola J, Rosmarin D, Rosenberg A, Van[...]

By sjmartinez • December 22, 2024

Tada Y, Armstrong AW, Imafuku S, Okubo Y, Morita A, Zhong Y, Zhuo J, Becker B, Napoli A, Banerjee S, Ohtsuki M. Deucravacitinib in Japanese[...]

By sjmartinez • December 7, 2024

Sadrolashrafi K, Hao A, Yamamoto RK, Guo L, Kikuchi R, Tolson HC, Bilimoria SN, Yee DK, Armstrong AW. The impact of insurance status on psoriasis[...]

By sjmartinez • December 2, 2024

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Mangin GD, Jacobson AA. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatol[...]

By sjmartinez • November 27, 2024

Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, Westley T, Kisa RM, Huang YH, Gao XH, Jo SJ, Armstrong AW. Indirect[...]

By sjmartinez • November 14, 2024

Guo L, Bilimoria SN, Kikuchi R, Hao A, Sadrolashrafi K, Yamamoto RK, Tolson H, Yee D, Armstrong AW. Chronic Obstructive Pulmonary Disease Outcomes in Psoriasis[...]

By sjmartinez • November 14, 2024